Efficacy of Cancer Support Programs: A Social Comparison Theory Analysis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

240 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-05-31

Study Completion Date

2019-03-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this research study is to learn if a support group program is acceptable for patients with prostate cancer or patients with breast cancer. Researchers also want to learn if the characteristics of the members of the support group program can have an effect on the quality of life of other members of the support group program. Support group programs will be conducted separately for prostate cancer patients and breast cancer patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Helping African American Prostate Cancer Survivors and Their Partners Cope With Challenges After Surgery for Prostate Cancer

NCT00869739

Cancer Survivor Depression Gastrointestinal Complications +4 more

COMPLETED NA

Problem Solving Therapy for Prostate Cancer Spousal Caregivers

NCT02085096

Prostate Cancer

COMPLETED NA

Positive Changes in Quality of Life of Older Cancer Patients and Their Caregivers

NCT00769249

Psychosocial Effects of Cancer and Its Treatment Unspecified Adult Solid Tumor, Protocol Specific

WITHDRAWN

Understanding Shared Psychobiological Pathways

NCT00245219

Breast Neoplasms

COMPLETED NA

The Role of Social Comparisons in Coping and Quality of Life Following a Prostate Cancer Diagnosis

NCT01176526

Prostate Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Screening Questionnaires:

Signing this consent form does not mean that you will be able to take part in this study. You will complete some questions about your mood to help researchers decide if you are eligible to take part in this study. It will take 10 to 15 minutes to complete these questions.

The researcher will discuss the questionnaire results with you and provide you with a list of community referrals and resources.

If your responses to the questions show that you are distressed, you will be eligible to take part in this study. If your responses to the questions show that you are not distressed, you will be randomly selected (as in the flip of a coin) to take part in this study.

If your responses to the questions show that you may harm yourself, a licensed psychologist will follow-up with you and make recommendations for future treatment.

Study Questionnaires:

If you are found to be eligible and are selected to take part in this study, you will be asked to complete questionnaires that will have questions about your medical history, quality of life, mood, thought processes, methods of coping with the disease, and support that you receive from others. It will take about 1 hour to complete these questionnaires.

Support Groups:

You will also take part in a support group program for either prostate or breast cancer patients. Each support group will be made up of about 10 members. Each group will meet 1 time each week for 10 weeks. Each meeting will last about 2 hours. At each meeting, patients will discuss and learn about methods of coping with the disease and ways to relax.

All meetings will be audio-recorded. Recordings will be reviewed by the research team to make sure that the groups are covering the program content.

Length of Study:

You will be on study for about 3 months.

End-of Study Questionnaires:

After the last support group meeting, you will complete questionnaires that will ask questions about your medical history, quality of life, mood, thought processes, methods of coping with the disease, and support that you receive from others. You will be off study after you have completed the end-of-study questionnaires.

This is an investigational study.

Up to 240 patients will take part in this study. Up to 204 will be enrolled at MD Anderson.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Homogeneous Support Group

Group Meetings

Intervention Type BEHAVIORAL

10 weekly group meetings lasting 2 hours.

Questionnaire

Intervention Type BEHAVIORAL

Surveys

Heterogeneous Support Group One

Group Meetings

Intervention Type BEHAVIORAL

10 weekly group meetings lasting 2 hours.

Questionnaire

Intervention Type BEHAVIORAL

Surveys

Heterogeneous Support Group Two

Group Meetings

Intervention Type BEHAVIORAL

10 weekly group meetings lasting 2 hours.

Questionnaire

Intervention Type BEHAVIORAL

Surveys

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Group Meetings

10 weekly group meetings lasting 2 hours.

Intervention Type BEHAVIORAL

Questionnaire

Surveys

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosis of prostate or breast cancer, regardless of treatment
2. No evidence of metastatic disease
3. Able to read, speak, and write English
4. Resides within one hour of M.D. Anderson Cancer Center
5. 21 years of age or older
6. Able to provide meaningful informed consent as judged by a research team member
7. Being a distressed patient: a T score greater than or equal to 63 on the Global Severity Index (GSI) of the Brief Symptom Inventory (BSI) or a T score greater than or equal to 63 on any two primary dimensions of this measure, or being a non-distressed patient: a T score of \< 63 on the GSI and a T score of \<63 on all primary dimensions of the BSI.